Diabetes, Lipid disorders and Public Health

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Diabetes

Lipid disorders

Public Health

Cholesterol’s Star Role in Dementia Prevention: New Insights from the 2024 Lancet Dementia Report

Cardiometabolic Health Congress

AUGUST 23, 2024

The 2024 report from the Lancet Standing Commission on Dementia Prevention, Intervention, and Care brings promising developments for healthcare professionals and public health advocates. As a leading cause of cardiovascular disease, dyslipidemia also has far-reaching implications for cognitive health, underscoring its broad impact.

Dementia

Dementia Cholesterol Risk Factors CME

FDA Approves Wegovy for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity

DAIC

MARCH 8, 2024

mg or placebo to cardiovascular standard of care in adults with overweight and obesity with established CVD and without diabetes. 1 The most common adverse event leading to discontinuation was gastrointestinal disorders, occurring in 10% of patients in the Wegovy group and 2% in the placebo group. 2 Wegovy 2.4 with placebo.

Obesity

Obesity Heart Disease Heart attacks Heart Attack

Cardiovascular Update

Cholesterol’s Star Role in Dementia Prevention: New Insights from the 2024 Lancet Dementia Report

FDA Approves Wegovy for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity

Stay Connected